İçeriğe geç
SON HABERLER
İş Dünyası

Isomorphic Labs Secures $5 Billion in Series C Funding

Isomorphic Labs raised $5 billion in Series C funding to scale its AI-driven drug design engine and advance its first candidates into clinical trials.

Isomorphic Labs Secures $5 Billion in Series C Funding

Isomorphic Labs, a UK-based biotechnology firm specializing in AI-driven drug discovery, has closed a $5 billion Series C funding round. The round was co-led by Greenoaks and Sequoia Capital, with participation from Alphabet, Andreessen Horowitz, Thrive Capital, GV, and Temasek. This capital injection brings the company’s total funding to $7.7 billion, marking a significant acceleration in institutional backing for AI-integrated pharmaceutical research.

The company plans to allocate these funds toward the development of its proprietary AI drug design engine, IsoDDE. Resources will also support the expansion of research into new biological domains and the establishment of the operational infrastructure required to transition initial drug candidates into clinical trials. This move signals a shift from purely computational research to active clinical development.

Founded in 2021 by Demis Hassabis, the company leverages research from DeepMind’s AlphaFold to simulate and design new drug molecules. By modeling molecular properties in a digital environment, the firm aims to compress the traditional drug development timeline. The company currently maintains active collaborations with major pharmaceutical entities, including Novartis, Eli Lilly, and Johnson & Johnson, focusing on oncology and immunology.

This funding follows a $2.1 billion investment round in May, reflecting a rapid increase in valuation and investor confidence in AI-native biotech models. The firm’s ability to secure such substantial capital in a high-interest-rate environment underscores the perceived market potential of AI in reducing the failure rates of drug discovery. Market observers should monitor the company’s progress in clinical trials, as these results will serve as a critical benchmark for the commercial viability of AI-designed therapeutics.

More stories

Son haberler